Accès ouvert déclaré2025article
Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial
Alex Luedtke, Youyi Fong, Lars van der Laan, Fei Heng, Ying Huang, Yiwen Lu, Chenchen Yu, Lindsay N. Carpp, Sanne Roels, Mathieu Le Gars, Griet A. Van Roey, Daniel J Stieh, Ilse Van Dromme, Avi Kenny, Marco Carone, Ollivier Hyrien, Victor Ayala, Lakshmi Jayashankar, Flora Castellino, Obrimpong Amoa-Awua, Manjula Basappa, Britta Flach, Bob C. Lin, Christopher A. Moore, Mursal Naisan, Muhammed Naqvi, Sandeep Narpala, Sarah O’Connell, Allen Mueller, Leo Serebryannyy, Mike Castro, Jennifer Wang, Gabrielle Dziubla, April K. Randhawa, Michele P. Andrasik, Jenny Hendriks, Carla Truyers, Frank Struyf, Hanneke Schuitemaker, Macaya Douoguih, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, Linda‐Gail Bekker, Nigel Garrett, Sandra Wagner Cardoso, Patrice Delafontaine, Craig A. Magaret, Johan Vingerhoets, Martín Casapía, Marcelo Losso, Susan J. Little, Aditya H. Gaur, Edith Swann, Christos J. Petropoulos, Adrian B. McDermott, Jerald Sadoff, Glenda Gray, Beatriz Grinsztejn, Paul Goepfert, Dean Follmann, Pavitra Roychoudhury, Alexander L. Greninger, Richard A. Koup, Rubén O. Donis, Peter B. Gilbert
1Citations signalées
29Institutions associées
6Pays d’affiliation
Résumé fourni par la source
In Latin American sites of the ENSEMBLE trial of the Ad26.COV2.S vaccine vs. placebo, binding antibodies and neutralizing antibodies measured 4 weeks post-vaccination (∼peak) against circulating lineages (Ancestral, Gamma, Lambda, Mu, Zeta) were assessed as a correlate of risk of, and correlate of protection against, lineage-specific COVID-19. Comparison of lineage-matched controlled vaccine efficacy (VE) curves showed similar relationships across lineages of lineage-specific antibody with VE against lineage-matched COVID-19, supporting a "variant-invariant correlate of protection model" that undergirds immunobridging inferences of efficacy against new variants based on variant-matched neutralizing antibody titers. Lambda departed from this model at undetectable/just-detectable titers: at ∼ peak Reference-specific titers of 2.7 arbitrary units (AU)/mL (just-detectable) and 30 AU/ml, VE against Ancestral COVID-19 was 53.0% (95% CI: 30.7%, 67.9%) and 84.5% (73.6%, 93.0%), respectively; at the same Lambda-specific titers, VE against Lambda COVID-19 was 12.3% (-54.1%, 50.3%) and 91.1% (68.9%, 98.0%). Additional research is needed for Omicron variants.
Sujets associés
SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesCOVID-19 Clinical Research Studies